Outcomes of frail patients undergoing high‐dose chemotherapy and autologous stem cell transplantation for multiple myeloma
Year: 2024
Type: article
Study design: Observational Study
Abstract: In patients with multiple myeloma (MM) not-eligible for autologous haematopoietic cell transplantation (autoHCT), a simplified frailty index (SFI) identifies frail patients at risk for poor outcomes, but data are limited for transplant-eligible patients. In this registry-based retrospective study, we used an adapted version of the SFI to determine the prevalence of frailty in patients ≥65 years of age with MM undergoing autoHCT. Out of 5563 patients, 37.9% of patients were classified as frail and although they had increased non-relapse mortality (NRM) and inferior overall survival, the NRM at 100 days remained low (<2%) compared with non-frail patients.
Source: British Journal of Haematology
DOI: 10.1111/bjh.19811
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Amgen, Bristol-Myers Squibb, Pfizer, Sanofi, Spectrum Pharmaceuticals, Celgene, Medical College of Wisconsin, Regeneron Pharmaceuticals, Prothena, Janssen Scientific Affairs, Incyte, Health Resources and Services Administration, Genentech, National Heart, Lung, and Blood Institute, Office of Naval Research, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Environmental Health Sciences
OpenAlex ID: W4403368268